Spirographic AI Becomes First Commercial Platform to Predict Albumin Binding Site Specificity -- Achieving 86.4% Accuracy Across 198 Drugs

Every existing commercial tool predicts only binary bound/unbound status. spirographic AI predicts which site — Site I, Site II, or Subdomain IB — with 93.8% sensitivity for high binders, from SMILES input alone. CORVALLIS, Ore., April 23, 2026 /PRNewswire/ -- Spirographic AI, LLC today...